Skip to main content

Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 26-50 of 125

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Status: Active
Location: 5 locations
Alternate Cabozantinib Dosing Schedule Alone and in Combination with Nivolumab for the Treatment of Metastatic Kidney Cancer and Neuroendocrine Tumors
Status: Active
Location: 5 locations
Sasanlimab, Palbociclib and Axitinib for the Treatment of Unresectable Advanced or Metastatic Renal Cell Carcinoma, The SPARCC Trial
Status: Active
Location: 5 locations
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Status: Active
Location: 5 locations
Trans-arterial Embolization before Percutaneous Cryosurgery for the Treatment of Kidney Cancer
Status: Active
Location: 5 locations
Tivozanib and Nivolumab for the Treatment of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma, The FORTUNE Trial
Status: Active
Location: 5 locations
Ceralasertib with or without Olaparib or Durvalumab in Treating Patients with Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 4 locations
Locally Ablative Therapy for the Treatment of Oligo-progressive Prostate Cancer, Urinary Tract Cancer or Kidney Cancer, LAYOVER Trial
Status: Active
Location: 4 locations
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
Status: Active
Location: 4 locations
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Status: Active
Location: 6 locations
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Status: Active
Location: 6 locations
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Status: Active
Location: 4 locations
Neoadjuvant Pembrolizumab and Axitinib for Treatment of Patients with Kidney Cell Carcinoma and Associated Inferior Vena Cava Tumor Thrombus, NEOPAX Trial
Status: Active
Location: 3 locations
Nivolumab, Relatlimab and Ipilimumab versus Nivolumab and Ipilimumab for the Treatment of Untreated Stage IV Renal Cell Cancer
Status: Active
Location: 3 locations
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Status: Active
Location: 3 locations
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Status: Active
Location: 3 locations
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Status: Active
Location: 3 locations
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Status: Active
Location: 3 locations
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Status: Active
Location: 3 locations
XL092 with or without Nivolumab for the Treatment of Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Location: 2 locations
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
Status: Active
Location: 2 locations
At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls
Status: Active
Location: 2 locations
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Status: Active
Location: 2 locations
A Beta-only IL-2 ImmunoTherapY Study
Status: Active
Location: 2 locations
Implantable Microdevice for the Delivery of Microdoses of Drugs to the Tumor in Patients with Metastatic Renal Cell Cancer
Status: Active
Location: 2 locations